Medication associated with fewer hospitalization days

XARELTO is associated with fewer hospitalization days and outpatient visits compared to warfarin in patients with non-valvular atrial fibrillation, according to data presented at the American Heart Association 2014 Scientific Sessions.

Xarelto may be alternative for cancer patients with VTE

Patients with cancer who have had venous thromboembolism may have lower risk of bleeding with XARELTO® (rivaroxaban) , a study in Lancet Haematology suggests

XARELTO safe for use with elderly, study finds

XARELTO® (rivaroxaban) is safe to use in elderly patients with nonvalvular atrial fibrillation, an analysis published in Circulation finds.